bluebird bio Inc expected to post a loss of $6.15 a share - Earnings Preview

bluebird bio

21/03/2025 13:06

bluebird bio Inc BLUE.OQ BLUE.O is expected to show a rise in quarterly revenue when it reports  results on March 24 (estimated) for the period ending December 31 2024

The Somerville Massachusetts-based  company is expected to report a 247.3% increase in revenue to $27.207 million from $7.83 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.The company's guidance on November 14 2024, for the period ended December 31, was for revenue of $25.000 million.

​LSEG's mean analyst estimate for bluebird bio Inc is for a loss of $6.15 per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for bluebird bio Inc is $8.00​, above​ its last closing price of $3.96. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-6.65
-7.29
-6.20
Beat
14.9
Jun. 30 2024
-9.96
-8.33
-8.40
Missed
-0.8
Mar. 31 2024
-8.83
-8.81
-7.20
Beat
18.3​
Dec. 31 2023
-13.01
-13.24
-15.60
Missed
-17.8
​​Sep. 30 2023
-13.45
-13.50
-13.20
Beat
2.2
Jun. 30 2023
-14.37
-14.31
-13.40
Beat
6.4​
Mar. 31 2023
-5.37
-7.40
4.20
Beat
156.8
Dec. 31 2022
-7.41
-8.72
-16.20
Missed
-85.8

This summary was machine generated March 21 at 13:06 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)